Advanced Peptide Nanomedicines for Bladder Cancer Theranostics

Abstract

Cancer is still a global public health problem. Although remarkable success has been achieved in cancer diagnosis and treatment, the high recurrence and mortality rates remain severely threatening to human lives and health. In recent years, peptide nanomedicines with precise selectivity and high biocompatibility have attracted intense attention in biomedical applications. In particular, there has been a significant increase in the exploration of peptides and their derivatives for malignant tumor therapy and diagnosis. Herein, we review the applications of peptides and their derivatives in the diagnosis and treatment of bladder cancer, providing new insights for the design and development of novel peptide nanomedicines for the treatment of bladder cancer in the future.

Keywords: bladder cancer; diagnosis; nanomedicines; peptide; treatment.

FIGURE 1

After intravesical instillation of NG/HCPT, the selective accumulation of nanodrugs in tumor tissue finally releases HCPT triggered by GSH(Guo et al., 2017).

FIGURE 2

(A) The molecular structure of HCPT-FF-GFLG-EEYSAYPDSVPMMS; (B) The illustration of the bladder tumor cell targeting, intracellular fibrillation and drug release of HCPT-FF-GFLG-EEYSAYPDSVPMMS(Zeng et al., 2021a).

FIGURE 3

Schematic illustration of synthesizing BBTD + GA/PEG-cRGD nanoparticles for photohyperthermia therapy of MIBC(Zeng et al., 2021a).

FIGURE 4

Bld-1-KLA destroys the mitochondrial membrane and induces apoptosis.